While pericarditis and other serosal membrane toxicities are theoretical on-target off-tumor toxicities of mesothelin-targeted therapeutics like LMB-100, these were the first two occurrences of pericarditis in pancreatobiliary cancer patients receiving LMB-100. This evidence concerns the gene MSLN and pericarditis.